Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) has been given an average rating of “Moderate Buy” by the eight analysts that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $24.40.
Several analysts recently weighed in on the company. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Wedbush lowered Alto Neuroscience from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $29.00 to $4.00 in a research note on Wednesday. Rodman & Renshaw downgraded shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday. RODMAN&RENSHAW lowered shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Finally, Robert W. Baird reduced their price objective on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday.
Get Our Latest Report on Alto Neuroscience
Institutional Investors Weigh In On Alto Neuroscience
Alto Neuroscience Stock Up 5.8 %
Shares of NYSE ANRO opened at $4.37 on Thursday. Alto Neuroscience has a 12-month low of $3.93 and a 12-month high of $24.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.85 and a current ratio of 19.85. The firm has a 50 day moving average of $12.02 and a 200 day moving average of $12.36.
Alto Neuroscience (NYSE:ANRO – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.07. Sell-side analysts expect that Alto Neuroscience will post -2.63 earnings per share for the current fiscal year.
About Alto Neuroscience
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Featured Stories
- Five stocks we like better than Alto Neuroscience
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is the Shanghai Stock Exchange Composite Index?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What is a Death Cross in Stocks?
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.